Muller, CEO of UPenn health system, to step down in 2019

Ralph W. Muller, MA, chief executive of the University of Pennsylvania’s health system in Philadelphia, will step down in 2019. Leading the school health system since 2003, he has helped it expand to six hospitals.

Penn acquired Chester County Hospital and Health System in 2013, Lancaster General Health in 2015, and Princeton HealthCare System in 2018.

“Ralph’s partnership, effective leadership, support of the academic mission and keen understanding of the evolving health care environment have been of great benefit to Penn Medicine and the university,” wrote University of Pennsylvania president Amy Gutmann and Perelman School of Medicine Dean J. Larry Jameson in a note to the Penn Medicine community.

Muller will step down June 30, 2019, allowing the health system nearly a year to conduct a wide search for candidates.

Muller, though, warned his successor may face growing instability. Megamergers in the industry could have major impacts, while uncertainty will continue to surround the Affordable Care Act.

""
Nicholas Leider, Managing Editor

Nicholas joined TriMed in 2016 as the managing editor of the Chicago office. After receiving his master’s from Roosevelt University, he worked in various writing/editing roles for magazines ranging in topic from billiards to metallurgy. Currently on Chicago’s north side, Nicholas keeps busy by running, reading and talking to his two cats.

Around the web

Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more. 

Updated compensation data includes good news for multiple subspecialties. The new report also examines private equity's impact on employment models and how much male cardiologists earn compared to females.

When drugs are on the FDA’s shortage list, outsourcing facilities can produce their own compounded versions. When the FDA removed tirzepatide from that list with no warning, it created a considerable amount of chaos both behind the scenes and in pharmacies all over the country. 

Trimed Popup
Trimed Popup